Bolt Biotherapeutics (FRA:6LP0) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6LP0 Bolt Biotherapeutics Inc FRA:6LP0
53 GF Score
Price €5.18
GF Value €12.42
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics FFO per Share?

FFO per Share only applies to REITs.

FRA:6LP0
53GF Score
Bolt Biotherapeutics Inc FRA:6LP0
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of €5.18 is trading 58.3% below its estimated GF Value™ of €12.42.

Key valuation signals for FRA:6LP0:

  • FFO per Share:
  • GF Value™: €12.42 vs. price of €5.18 (58.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bolt Biotherapeutics Business Description

Other Exchanges BOLT:USA
Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
53GF Score

Get the complete analysis for FRA:6LP0

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.18
Price
€12.42
GF Value